Market Cap 393.06B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 21.83
Forward PE 15.56
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 9,646,000
Avg Vol 6,053,388
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 8%
Beta 0.32
Analysts Strong Sell
Price Target $251.55

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
BeyondtheCouch
BeyondtheCouch Jun. 19 at 8:21 PM
$ABBV $APGE $VKTX show me you sold out early and are trying to justify it without telling me
0 · Reply
DG20
DG20 Jun. 19 at 7:49 PM
$ABBV $VKTX An almost $400 billion company invests $11 billion in their core immunology business and you think that they’ve given up on obesity? There is a ton of literature coming out, showing that GLP medicines are good adjunctive drugs for autoimmune pathologies. Also, obesity itself clinically worsens many inflammatory diseases that AbbVie already treats —> psoriasis/arthritis, hidradenitis, inflammatory bowel disease, rheumatoid arthritis etc… $ABBV also owns a cosmetics business and the GLP connection is incredibly obvious. I am not suggesting Abbvie is going to buy Viking (maybe KLRA/GPCR) but what I am suggesting is they will 100% purchase more obesity assets which their mgmt team has repeatedly eluded to… @biolover understands what you never will, the actual problems being treated not just the superficial market noise…
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 19 at 7:01 PM
$SLS $ABBV $RHHBY $BMY have Long Term VIALE-C, VIALE-M VIALE-T Phase 3 Data - for PATIENTS IN TRIAL - Getting Extra Ordinary In Trial Treatment ... There is NIL Survival beyond 20 months for any AML CR2 Patients, on BAT, ABSENT TRANSPLANT. - *** Ask any of the SHORT LYING LOWLIFE SCUMBAGS to Show You 1 - Just 1 Trial - with IN TRIAL Patients, ALL r/R AML who obtain a Second Remission CR2 - Which WILL INCLUDE ANY- SO CALLED - Healthiest transplant Ineligible Patients - with any Survival Past 20 months ... -- You'll Get CRICKETs. As I posted Yesterday - ANGIE - May Like to Surprise the STREET and Plug these SCUMBAGS with a tasty Amuse-Bouche - and DISCLOSE the 80th Event and include the Number of EVENTS in the BAT and GPS Treatment Arms --- 55-60 / 20-25 --- --- as the IDMC has that DATA Immediately Upon the 80th.
0 · Reply
History101
History101 Jun. 19 at 6:14 PM
$APGE news is out that $ABBV is buying APGE for a big premium. APGE was one of 3 buyout targets (other 2 were $COGT & $INBX) mentioned by the biotech analyst on CNBC Fast Money last night..
0 · Reply
chuckieclam
chuckieclam Jun. 19 at 5:27 PM
$ABBV $VKTX do they want Viking or is it going to MRK AZN or someone else? better hurry!
1 · Reply
GreenHawkz
GreenHawkz Jun. 19 at 4:58 PM
$VKTX and $ABBV goes for $APGE for $11B. Another @biolover failure 😂😂 Greedy BL running out of options. No one left to buy this junk! Time to bring this shithole co to low teens
2 · Reply
Oldpuck
Oldpuck Jun. 19 at 4:50 PM
$ABBV Hope this works out better than ROVA:-T and Emraciline did both total busts from their last 2 buyouts. Not expecting much.
0 · Reply
jdlman
jdlman Jun. 19 at 4:25 PM
$ABBV i thinks this goes down more on Monday
0 · Reply
WallStJesus
WallStJesus Jun. 19 at 4:02 PM
0 · Reply
tinsam81
tinsam81 Jun. 19 at 3:02 PM
$ABBV so we drop more on Monday based on this News?
1 · Reply
Latest News on ABBV
AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 1 day ago

AbbVie Declares Quarterly Dividend


AbbVie announces EC authorizes expanded label for Venclyxto

2026-05-29T13:20:36.000Z - 21 days ago

AbbVie announces EC authorizes expanded label for Venclyxto


US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 23 days ago

US FDA approves AbbVie's rare blood cancer drug


AbbVie reports positive CHMP opinion for Maviret

2026-05-22T12:12:15.000Z - 4 weeks ago

AbbVie reports positive CHMP opinion for Maviret


AbbVie price target lowered to $235 from $236 at Evercore ISI

2026-05-15T12:51:42.000Z - 5 weeks ago

AbbVie price target lowered to $235 from $236 at Evercore ISI


AbbVie price target raised to $298 from $294 at Piper Sandler

2026-05-14T11:07:12.000Z - 5 weeks ago

AbbVie price target raised to $298 from $294 at Piper Sandler


AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 6 weeks ago

AbbVie Transcript: AGM 2026


AbbVie price target raised to $236 from $232 at Evercore ISI

2026-05-04T12:13:35.000Z - 6 weeks ago

AbbVie price target raised to $236 from $232 at Evercore ISI


AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Earnings Call Transcript: Q1 2026


AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Earnings release: Q1 2026


AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Quarterly report: Q1 2026


AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 7 weeks ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth


AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 7 weeks ago

AbbVie Reports First-Quarter 2026 Financial Results


US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment


Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 2 months ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation


AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call


AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 3 months ago

AbbVie Proxy statement: Proxy filing


AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 3 months ago

AbbVie Proxy statement: Proxy filing


BeyondtheCouch
BeyondtheCouch Jun. 19 at 8:21 PM
$ABBV $APGE $VKTX show me you sold out early and are trying to justify it without telling me
0 · Reply
DG20
DG20 Jun. 19 at 7:49 PM
$ABBV $VKTX An almost $400 billion company invests $11 billion in their core immunology business and you think that they’ve given up on obesity? There is a ton of literature coming out, showing that GLP medicines are good adjunctive drugs for autoimmune pathologies. Also, obesity itself clinically worsens many inflammatory diseases that AbbVie already treats —> psoriasis/arthritis, hidradenitis, inflammatory bowel disease, rheumatoid arthritis etc… $ABBV also owns a cosmetics business and the GLP connection is incredibly obvious. I am not suggesting Abbvie is going to buy Viking (maybe KLRA/GPCR) but what I am suggesting is they will 100% purchase more obesity assets which their mgmt team has repeatedly eluded to… @biolover understands what you never will, the actual problems being treated not just the superficial market noise…
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 19 at 7:01 PM
$SLS $ABBV $RHHBY $BMY have Long Term VIALE-C, VIALE-M VIALE-T Phase 3 Data - for PATIENTS IN TRIAL - Getting Extra Ordinary In Trial Treatment ... There is NIL Survival beyond 20 months for any AML CR2 Patients, on BAT, ABSENT TRANSPLANT. - *** Ask any of the SHORT LYING LOWLIFE SCUMBAGS to Show You 1 - Just 1 Trial - with IN TRIAL Patients, ALL r/R AML who obtain a Second Remission CR2 - Which WILL INCLUDE ANY- SO CALLED - Healthiest transplant Ineligible Patients - with any Survival Past 20 months ... -- You'll Get CRICKETs. As I posted Yesterday - ANGIE - May Like to Surprise the STREET and Plug these SCUMBAGS with a tasty Amuse-Bouche - and DISCLOSE the 80th Event and include the Number of EVENTS in the BAT and GPS Treatment Arms --- 55-60 / 20-25 --- --- as the IDMC has that DATA Immediately Upon the 80th.
0 · Reply
History101
History101 Jun. 19 at 6:14 PM
$APGE news is out that $ABBV is buying APGE for a big premium. APGE was one of 3 buyout targets (other 2 were $COGT & $INBX) mentioned by the biotech analyst on CNBC Fast Money last night..
0 · Reply
chuckieclam
chuckieclam Jun. 19 at 5:27 PM
$ABBV $VKTX do they want Viking or is it going to MRK AZN or someone else? better hurry!
1 · Reply
GreenHawkz
GreenHawkz Jun. 19 at 4:58 PM
$VKTX and $ABBV goes for $APGE for $11B. Another @biolover failure 😂😂 Greedy BL running out of options. No one left to buy this junk! Time to bring this shithole co to low teens
2 · Reply
Oldpuck
Oldpuck Jun. 19 at 4:50 PM
$ABBV Hope this works out better than ROVA:-T and Emraciline did both total busts from their last 2 buyouts. Not expecting much.
0 · Reply
jdlman
jdlman Jun. 19 at 4:25 PM
$ABBV i thinks this goes down more on Monday
0 · Reply
WallStJesus
WallStJesus Jun. 19 at 4:02 PM
0 · Reply
tinsam81
tinsam81 Jun. 19 at 3:02 PM
$ABBV so we drop more on Monday based on this News?
1 · Reply
LiveSquawk
LiveSquawk Jun. 19 at 2:17 PM
$ABBV | AbbVie Closes In On Nearly $11 Bln Deal For Biotech Apogee Therapeutics – FT https://www.ft.com/content/cb5e94aa-1687-47fe-b55a-82e273e8b1bd?shareType=nongift
0 · Reply
WhatsUpWhatsNot
WhatsUpWhatsNot Jun. 19 at 2:04 PM
$BLIN it’s days like this and stocks like $ABBV that make me more comfortable with $BLIN
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 18 at 9:19 PM
$SLS Monday will be the 44th Day since the 78th Event. 72nd Dec 26th - 78th May 11 --- 6 Events in 136 Days / Approximately 1 Event Every 22 Days... -- > Monday is the Bullseye to see the 80th Event PR - and for the INCH THICK IDIOT Tools, the reason the Share Price Launched on each of the Previous Event PR's, is the Same Reason, it will Just about double to $18/ $20 on the 80th ... That is - SMART MONEY ... Much Smarter than US ( $ABBV / $RHHBY $BMY) Knows BAT does not offer effective Remission Maintenance - they Know its Gps Doing what its done in all 7 Prior Trials --- Prevent Relapse and Extend Survival - that is Directly Correlated with Immune Response- The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA From the INTERIM ANALYSIS at 60 Events... You penny flipping idiots are going regret for the rest of your Miserable Short Lives, for selling for anything less than $80 Per Share --- now you know.
0 · Reply
focafoca99
focafoca99 Jun. 18 at 8:30 PM
$ABBV paid a quarterly cash dividend of $1.73 per share, payable August 14 to shareholders of record July 15. https://www.rapidticker.com/news/abbv-abbvie-declares-quarterly-dividend-6cd3ba
0 · Reply
biolover
biolover Jun. 18 at 7:35 PM
$VKTX rumors $ABBV jets clustered somewhere remote 😂. I personally don’t beleive Abbv will wait long. Could be Vk could be $KLRA These calls could go up 100.000% last 2 year sentiment suggests otherwise but u never know ..
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 18 at 6:56 PM
$ABBV $MRK $PFE $SLS Shorts Dr. Stergiou spelled it out for you “We are strategically transitioning from a clinical-stage biotech company into a late-stage organization on the cusp of commercialization.” ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 18 at 6:42 PM
$ABBV $MRK $PFE $SLS “The second half of 2026 is poised to be one of the most catalyst-rich periods in SELLAS history. We are strategically transitioning from a clinical-stage biotech company into a late-stage organization on the cusp of commercialization. "At SELLAS, we are no longer simply talking about what could happen. Increasingly, we are talking about what is happening." This progress belongs to our extraordinary team-the scientists, physicians, clinical teams, and employees who work relentlessly every day.” 🎤 ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 18 at 6:41 PM
$ABBV $MRK $PFE $SLS Close money green $9.00+ ✌️🙏❤️‍🩹
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 18 at 6:32 PM
$SLS Monday will be the 44th Day since the 78th Event. 72nd Dec 26th - 78th May 11 --- 6 Events in 136 Days / Approximately 1 Event Every 22 Days... -- > Monday is the Bullseye to see the 80th Event PR - and for this Board Full of INCH THICK IDIOT Tools, the reason the Share Price Launched on each of the Previous Event PR's, is the Same Reason, it will Just about double to $18/ $20 on the 80th ... That is - SMART MONEY ... Much Smarter than US ( $ABBV / $RHHBY $BMY) Knows BAT does not offer effective Remission Maintenance - they Know its Gps Doing what its done in all 7 Prior Trials --- Prevent Relapse and Extend Survival - that is Directly Correlated with Immune Response- The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA From the INTERIM ANALYSIS at 60 Events... You penny flipping idiots are going regret for the rest of your Miserable Short Lives, for selling for anything less than $80 Per Share --- now you know.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 18 at 6:19 PM
$ABBV $MRK $PFE $SLS Dr. Angelos Stergiou 🤩✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 18 at 6:12 PM
$ABBV $MRK $PFE $SLS Dr. Angelos Stergiou spelled it out for Shorts but they are blinded and close minded by their greed to even consider what’s going on here “To understand why, here is a "Building" analogy: • Traditional Chemotherapy: Indiscriminately destroys the entire building to get the villain. • Targeted Therapy: Precise, but vulnerable the moment the villain changes their appearance (clonal escape). • Immunotherapy: Trains an adaptive security force to patrol the building. They recognize the villain regardless of the disguise, keeping the structure intact. We are moving toward a world where we can hopefully treat the fundamental biology of AML. Our mission is to move past “managing" the disease and toward potentially establishing curative outcomes as the standard of care-preserving the "building" while eliminating the threat for good. ✌️🙏❤️‍🩹
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 18 at 6:10 PM
$SLS Monday will be the 44th Day since the78th Event. 72nd Dec 26th - 78th May 11 --- / 6 Events in 136 Days / Approximately 1 Event Every 22 Days... Monday is the Bullseye to see the 80th Event PR - and for this Board Full of INCH THICK IDIOT Tools, the reason the Share Price Launched on each of the Previous Event PR's, is the Same Reason, it will Just about double to $18/ $20 on the 80th ... That is - SMART MONEY ... Much Smarter than US ( $ABBV / $RHHBY $BMY) Knows BAT does not offer effective Remission Maintenance - they Know its Gps Doing what its done in all 7 Prior Trials --- Prevent Relapse and Extend Survival - that is Directly Correlated with Immune Response- The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA From the INTERIM ANALYSIS at 60 Events... You penny flipping idiots are going regret for the rest of your Miserable Short Lives, for selling for anything less than $80 Per Share --- now you know.
0 · Reply